Cyclin-dependent kinases: molecular switches controlling anergy and potential therapeutic targets for tolerance.

A large body of research has established the importance of costimulatory signals and proliferation for the generation of productive T cell immune responses. While costimulation and cell cycle progression are each individually necessary for CD4+ effector T cell differentiation, it has become clear that neither of these processes alone is sufficient to avoid anergy. This review outlines the links between T cell differentiation, tolerance, and the cell cycle, and highlights recent work that has implicated cyclin-dependent kinases as important regulators and potential targets for modulation of T cell immunity and tolerance.

[1]  Paul Greengard,et al.  Pharmacological inhibitors of cyclin-dependent kinases. , 2002, Trends in pharmacological sciences.

[2]  Ronald H. Schwartz,et al.  Selective, stable demethylation of the interleukin-2 gene enhances transcription by an active process , 2003, Nature Immunology.

[3]  A. Wells,et al.  Opposing Roles for the Cyclin-Dependent Kinase Inhibitor p27kip1 in the Control of CD4+ T Cell Proliferation and Effector Function1 , 2005, The Journal of Immunology.

[4]  R. Schwartz,et al.  Multifactor cis-dominant negative regulation of IL-2 gene expression in anergized T cells. , 1996, Journal of immunology.

[5]  Chyung-Ru Wang,et al.  Helper T cell differentiation is controlled by the cell cycle. , 1998, Immunity.

[6]  Y. Iwamoto,et al.  A pathway regulated by cell cycle inhibitor p27Kip1 and checkpoint inhibitor Smad3 is involved in the induction of T cell tolerance , 2006, Nature Immunology.

[7]  B. Freedman,et al.  Regulation of T Cell Activation and Tolerance by Phospholipase Cγ-1-Dependent Integrin Avidity Modulation1 , 2003, The Journal of Immunology.

[8]  D. Franklin,et al.  An Important Role of CDK Inhibitor p18INK4c in Modulating Antigen Receptor-Mediated T Cell Proliferation1 , 2001, The Journal of Immunology.

[9]  A. Wells,et al.  The role of cyclin-dependent kinases in T-cell development, proliferation, and function. , 2006, Critical reviews in immunology.

[10]  James M. Roberts,et al.  Cloning of p27 Kip1 , a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals , 1994, Cell.

[11]  M. Jenkins,et al.  Clonal anergy is induced in vitro by T cell receptor occupancy in the absence of proliferation. , 1991, Journal of immunology.

[12]  M. Serrano,et al.  The cell cycle inhibitor p21 controls T-cell proliferation and sex-linked lupus development , 2000, Nature Medicine.

[13]  D. Mueller,et al.  Evidence for repression of IL-2 gene activation in anergic T cells. , 1999, Journal of immunology.

[14]  A. Wells,et al.  Signals from CD28 Induce Stable Epigenetic Modification of the IL-2 Promoter1 , 2005, The Journal of Immunology.

[15]  G. Nabel,et al.  Regulation of NF-κB by Cyclin-Dependent Kinases Associated with the p300 Coactivator , 1997, Science.

[16]  A. Senderowicz Targeting cell cycle and apoptosis for the treatment of human malignancies. , 2004, Current opinion in cell biology.

[17]  D. Mueller E3 ubiquitin ligases as T cell anergy factors , 2004, Nature Immunology.

[18]  R. Schwartz T cell anergy. , 2003, Annual review of immunology.

[19]  P. Fields,et al.  Blocked Ras Activation in Anergic CD4+ T Cells , 1996, Science.

[20]  K. Wood,et al.  Regulatory lymphocytes: Regulatory T cells in transplantation tolerance , 2003, Nature Reviews Immunology.

[21]  Fang Liu,et al.  Cyclin-dependent kinases regulate the antiproliferative function of Smads , 2004, Nature.

[22]  R. Schwartz,et al.  The -180 site of the IL-2 promoter is the target of CREB/CREM binding in T cell anergy. , 1999, Journal of immunology.

[23]  B. Verdoodt,et al.  The cyclin‐dependent kinase inhibitors p27Kip1 and p21Cip1 are not essential in T cell anergy , 2003, European journal of immunology.

[24]  E. Palmer,et al.  Quantifying the Frequency of Alloreactive T Cells In Vivo: New Answers to an Old Question1 , 2001, The Journal of Immunology.

[25]  A. Senderowicz Novel Small Molecule Cyclin-Dependent Kinases Modulators in Human Clinical Trials , 2003, Cancer biology & therapy.

[26]  A. Wells T-Cell Costimulatory Pathways Relevant to Transplant Rejection and Tolerance , 2002 .

[27]  J. Gribben,et al.  Prevention of T cell anergy by signaling through the gamma c chain of the IL-2 receptor. , 1994, Science.

[28]  J. Gribben,et al.  Differential association of protein tyrosine kinases with the T cell receptor is linked to the induction of anergy and its prevention by B7 family-mediated costimulation , 1996, The Journal of experimental medicine.

[29]  M. Croft,et al.  Deficiency of the Cyclin Kinase Inhibitor p21(WAF-1/CIP-1) Promotes Apoptosis of Activated/Memory T Cells and Inhibits Spontaneous Systemic Autoimmunity , 2004, The Journal of experimental medicine.

[30]  Kenneth M. Murphy,et al.  Decision making in the immune system: The lineage decisions of helper T cells , 2002, Nature Reviews Immunology.

[31]  V. D’Agati,et al.  Reversal of collapsing glomerulopathy in mice with the cyclin-dependent kinase inhibitor CYC202. , 2004, Journal of the American Society of Nephrology : JASN.

[32]  Nikolai Zhelev,et al.  In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R‐roscovitine) , 2002, International journal of cancer.

[33]  J. Gribben,et al.  Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[34]  L. Turka,et al.  T Cell Effector Function and Anergy Avoidance Are Quantitatively Linked to Cell Division1 , 2000, The Journal of Immunology.

[35]  J. Ikeda,et al.  Cyclin-dependent kinases as a therapeutic target for stroke. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[36]  A. Mondino,et al.  Blocked Signal Transduction to the ERK and JNK Protein Kinases in Anergic CD4+ T Cells , 1996, Science.

[37]  P. Allen,et al.  Selective activation of the calcium signaling pathway by altered peptide ligands , 1996, The Journal of experimental medicine.

[38]  A. Khoruts,et al.  Antagonistic Roles for CTLA-4 and the Mammalian Target of Rapamycin in the Regulation of Clonal Anergy: Enhanced Cell Cycle Progression Promotes Recall Antigen Responsiveness1 , 2001, The Journal of Immunology.

[39]  Brian D. Dynlacht,et al.  Regulation of transcription by proteins that control the cell cycle , 1997, Nature.

[40]  S. Ely,et al.  Homeostatic cell-cycle control by BLyS: Induction of cell-cycle entry but not G1/S transition in opposition to p18INK4c and p27Kip1. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[41]  A. Wells,et al.  The Cyclin-Dependent Kinase Inhibitor p27kip1 Is Required for Transplantation Tolerance Induced by Costimulatory Blockade1 , 2006, The Journal of Immunology.

[42]  Christopher Haslett,et al.  Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis , 2006, Nature Medicine.

[43]  H. Gudmundsdottir,et al.  Dynamics and requirements of T cell clonal expansion in vivo at the single-cell level: effector function is linked to proliferative capacity. , 1999, Journal of immunology.

[44]  K. Gilbert,et al.  The ability of antigen, but not interleukin‐2, to promote n‐butyrate‐induced T helper 1 cell anergy is associated with increased expression and altered association patterns of cyclin‐dependent kinase inhibitors , 2002, Immunology.

[45]  K. Gilbert,et al.  Induction of Anergy in Th1 Cells Associated with Increased Levels of Cyclin-Dependent Kinase Inhibitors p21Cip1 and p27Kip1 1 , 2001, The Journal of Immunology.

[46]  P. Linsley,et al.  Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation , 1991, The Journal of experimental medicine.

[47]  Laurie A. Smith,et al.  Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine , 2006, Nature.

[48]  P. Hodgkin,et al.  Cell division regulates the T cell cytokine repertoire, revealing a mechanism underlying immune class regulation. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[49]  J. Allison,et al.  CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones , 1992, Nature.

[50]  T. Ushijima,et al.  A specific CpG site demethylation in the human interleukin 2 gene promoter is an epigenetic memory , 2006, The EMBO journal.

[51]  R. Schwartz,et al.  Reversal of in vitro T cell clonal anergy by IL-2 stimulation. , 1992, International immunology.

[52]  S. Ely,et al.  CDK inhibitor p18(INK4c) is required for the generation of functional plasma cells. , 2002, Immunity.

[53]  D. Kono,et al.  Role of Cyclin Kinase Inhibitor p21 in Systemic Autoimmunity1 2 , 2001, The Journal of Immunology.

[54]  R. Schwartz,et al.  Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation. , 1999, Journal of immunology.

[55]  G. Freeman,et al.  Maintenance of human T cell anergy: blocking of IL-2 gene transcription by activated Rap1. , 1997, Science.

[56]  H. Gudmundsdottir,et al.  Following the fate of individual T cells throughout activation and clonal expansion. Signals from T cell receptor and CD28 differentially regulate the induction and duration of a proliferative response. , 1997, The Journal of clinical investigation.

[57]  W. Feeser,et al.  Anergic T cells are defective in both jun NH2-terminal kinase and mitogen-activated protein kinase signaling pathways , 1996, The Journal of experimental medicine.

[58]  J. Bluestone,et al.  Signaling through CD28 and CTLA-4 controls two distinct forms of T cell anergy. , 2001, The Journal of clinical investigation.

[59]  Chou-Chi H. Li,et al.  Association of Cdk2/Cyclin E and NF-κB Complexes at G1/S Phase , 1998 .

[60]  P. Linsley,et al.  Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways , 1996, Nature.

[61]  G. Freeman,et al.  p27kip1 functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes , 2000, Nature Medicine.

[62]  James M. Roberts,et al.  CDK inhibitors: positive and negative regulators of G1-phase progression. , 1999, Genes & development.

[63]  J. Powell The induction and maintenance of T cell anergy. , 2006, Clinical immunology.

[64]  Anjana Rao,et al.  Transcriptional Mechanisms Underlying Lymphocyte Tolerance , 2002, Cell.

[65]  J. Harbour,et al.  The Rb/E2F pathway: expanding roles and emerging paradigms. , 2000, Genes & development.